Insider Trading Activity For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Pete A Meyers , CFO of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) reportedly Bought 350 shares of the company’s stock at an average price of 55.45 for a total transaction amount of $19,407.50 SEC Form
Insider Trading History For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Analyst Ratings For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
These are 1 Sell Rating, 3 Buy Ratings .
The current consensus rating for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is Buy (Score: 2.50) with a consensus target price of $73.25 , a potential (31.34% upside)
Analyst Ratings History For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
- On 11/2/2016 William Blair Boost Price Target of rating Outperform with a price target of $83.00 to $97.00
- On 7/27/2017 Mizuho Lower Price Target of rating Underperform to Underperform with a price target of $57.00 to $40.00
- On 7/27/2017 Royal Bank Of Canada Lower Price Target of rating Outperform to Outperform with a price target of $94.00 to $81.00
- On 8/9/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $75.00
Recent Trading Activity for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Shares of Eagle Pharmaceuticals, Inc. closed the previous trading session at 55.77 up +1.67 3.09% with 324,393 shares trading hands.